Everything below concerns IGF-1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
== Summary table for numbers of each class of nuclides == This is a summary table from List of nuclides. Numbers are not exact and may change slightly in the future, as nuclides are observed to be radioactive, or new half-lives are determined to some precision.
Émile Zuckerkandl (July 4, 1922 – November 9, 2013) was an Austrian-born French biologist considered one of the founders of the field of molecular evolution. He introduced, with Linus Pauling, the concept of the "molecular clock", which enabled the neutral theory of molecular evolution.
The Southern Rhodesian economy grew considerably during the war despite the concurrent rise of war expenditure to pay for the expansion of the military and the air training scheme. Expenditure on the war grew from £1,793,367 in the financial year 1940–41 to £5,334,701 in 1943–44—total Southern Rhodesian expenditure on the air training scheme was £11,215,522. These sums, while tiny compared to those incurred by larger nations, were enormous when scaled against the white population of less than 70,000 that accounted for most of the colony's economic output. Annual costs for the air training scheme alone far exceeded the pre-war national budget. Southern Rhodesia was then the second largest gold producer in the world, after South Africa. The colony's gold output had expanded greatly during the 1930s, and it remained the territory's main source of income during the war, though many extracting operations were diverted towards strategic minerals, most prominently chrome and asbestos. Southern Rhodesia became one of the two main sources of chrome for the Allies (South Africa was the other) and the world's third largest producer of asbestos after Canada and the Soviet Union. By the end of the war the mines at Shabani and Mashaba were turning out 1.5 million tonnes of asbestos a year, in addition to 600,000 tonnes of chrome. Gold output reached peak levels in 1941–42 and thereafter subsided. Southern Rhodesia also exported tungsten, mica and tin, and provided coal for the copper mines of Northern Rhodesia and the Congo.
Sources: en.wikipedia.org
Passive smoke is a mixture of smoke from the burning end of a cigarette, pipe or cigar, and the smoke exhaled from the lungs of smokers. It is involuntarily inhaled, lingers in the air hours after cigarettes have been extinguished, and may cause a wide range of adverse health effects, including cancer, respiratory infections, and asthma. Studies have shown that exposure to passive smoke causes harmful effects on the cardiovascular system and is associated with prevalent heart failure among non-smokers. Non-smokers who are exposed to passive smoke at home or work are thought, due to a wide variety of statistical studies, to increase their heart disease risk by 25–30% and their lung cancer risk by 20–30%. According to the World Health Organization, passive smoke is reported to kill about 1 million people per year and causes numerous diseases including cancer and heart diseases. The current US Surgeon General's Report concludes that there is no established risk-free level of exposure to passive smoke. Short exposures to passive smoke are believed to cause blood platelets to become stickier, damage the lining of blood vessels, decrease coronary flow velocity reserves, and reduce heart rate variability, potentially increasing the mortality of heart attacks. New research indicates that private research conducted by cigarette company Philip Morris in the 1980s showed that passive smoke was toxic, yet the company suppressed the finding during the next two decades.
=== 29 April === The Moscow-installed governor of Crimea, Sergei Aksyonov, blamed Ukrainian drones for a strike on a fuel storage facility in Sevastopol. According to the governor, two drones were shot down by air defence and electronic warfare systems. A Ukrainian intelligence spokesperson, Andriy Yusov, told Ukrainian media that "10 tanks of oil products", with 40,000 tons of fuel, were destroyed; called it divine retribution for those killed in Russian air strikes in Uman the previous day.
=== MAGNET designation === In 2008, Southern Ohio Medical Center became the first hospital in the tri-state region (Ohio, Kentucky, West Virginia) to earn Magnet Recognition from the American Nurses Credentialing Center. The Magnet Recognition Program recognizes healthcare organizations for quality patient care, nursing excellence and innovations in professional nursing practice. In 2011, less than 7% of hospitals in the United States were able to achieve Magnet Recognition. SOMC earned Magnet re-designation in 2013.
Currently, therapeutic strategies are being studied to help improve the communication between different cells in this pancreatic region by diving deeper into the cellular functions of these very cells and the regions they islet regions they reside in. The current studies being done mainly focus on diabetes and preventing the adverse effects it poses on mammalian organisms. The studies being done now focus heavily on the potential for stem-cell therapeutics or the development of different pharmaceuticals to help limit this condition.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.